Hydroquinone compounds, preparation methods therefor, and use in anti-tumor or immunomodulation therapy

11738,000

16/988525

August 07, 2020

Disclosed are hydroquinone compounds, preparation methods therefor, and uses thereof in anti-tumor or immunomodulation. The structural formula of the hydroquinone compounds are shown by formula I, [chemical expression included] wherein X is C═O or CH2; Y is NH, O or absent; R is: a substituted or unsubstituted alkyl group having at least one carbon atom, a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms; and a substituted or unsubstituted aryl group or heteroaryl group containing at least four carbon atoms. The compounds provided slowly release 2-tert-butyl-4-methoxyphenol in vivo and maintain stable plasma concentration of 2-tert-butyl-4-methoxyphenol (T1/2=12-24 h). The compounds provided by the present invention protect the phenolic hydroxyl group of 2-tert-butyl-4-methoxyphenol, avoids environmental oxidation and increase the environmental stability of drugs containing the compounds.

Biomedical Analysis Center, Academy Of Military Medical Sciences (Beijing, CN); Institute Of Pharmacology And Toxicology, Academy Of Military Medical Sciences (Beijing, CN)

BIOMEDICAL ANALYSIS CENTER, ACADEMY OF MILITARY MEDICAL SCIENCES (Beijing, CN), INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY, ACADEMY OF MILITARY MEDICAL SCIENCES (Beijing, CN)

1. An anti-tumor drug or immunomodulation drug, comprising an effective amount of a compound of formula I, [chemical expression included] wherein X is C═O; Y is absent; R is selected from any one of the following groups: 1) a substituted or unsubstituted cycloalkyl group having at least three carbon atoms, 2) a substituted or unsubstituted alkenyl group or alkynyl group having at least two carbon atoms, wherein a substituent is an amino group, a nitro group, a carbonyl group, amino acid derivatives, a natural flavorne, a natural alkaloid, a polyethylene glycol, a polyglutamic, acid or a polysaccharide, 3) an unsubstituted aryl or heteroaryl group having at least 4 carbon atoms, wherein the unsubstituted aryl or heteroaryl group is a naphthalene ring, an indole, a pyridine, a purine, a pyrimidine, an imidazole, a furan, or a pyrrole, 4) a substituted aryl or heteroaryl group having at least 4 carbon atoms, wherein the substituted aryl or heteroaryl group is a naphthalene ring, an indole, a purine, a pyrimidine, an imidazole, a furan or a benzoheterocycle, and wherein a substituent is a halo, an amino group, a nitro group, an ester group, a carbonyl group, amino acid derivatives, a natural flavone, a natural alkaloid, a polyethylene glycol, a polyglutamic acid, or polysaccharide, or pharmaceutically acceptable salts thereof, hydrates thereof, solvates thereof, or a pharmaceutical composition thereof as an active component.

2. The anti-tumor drug or immunomodulation drug of claim 1 , wherein the drug releases 2-tert-butyl-4-methyoxyphenyl.

4649219 March 1987 Itoh et al.
5362615 November 1994 Hagemann et al.
6127350 October 2000 Niesor et al.
6403639 June 2002 Ishikawa
1192148 September 1998
1937384 February 1971
1308311 May 2003
S54147038 November 1979
S5584934 June 1980
H09278741 October 1997
2009256214 November 2009
2042659 August 1995

Dilli et al., Journal of Chromatography (1977), 133(2), 363-6. cited by examiner
Jha et al., Biochemical Pharmacology (1984), 33(12), 1893-5. cited by examiner
Shindo et al., Biochemical and Biophysical Research Communications (2013), 436(2), 212-216. cited by examiner
Wattenberg, L., “Chemoprevention of Cancer,” Cancer Research, vol. 45, No. 1, Jan. 1985, 9 pages. cited by applicant
Prochaska, H. et al., “Specificity of Induction of Cancer Protective Enzymes by Analogues of Tert-Butyl-4-Hydroxyanisole (BHA),” Biochemical Pharmacology, vol. 34, No. 21, Nov. 1, 1985, 7 pages. cited by applicant
Chung, F. et al., “Effects of Butylated Hydroxyanisole on the Tumorigenicity and Metabolism of N-Nitrosodimethylamine and N-Nitrosopyrrolidine in A/J Mice,” Cancer Research, vol. 46, No. 1, Jan. 1986, 5 pages. cited by applicant
Williams, G. et al., “Safety Assessment of Butylated Hydroxyanisole and Butylated Hydroxytoluene as Antioxidant Food Additives,” Food and Chemical Toxicology, vol. 37, No. 9-10, Sep. 1999, 12 pages. cited by applicant
Leclercq, C. et al., “Estimates of the theoretical maximum daily intake of erythorbic acid, gallates, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT) in Italy: a stepwise approach,” Food and Chemical Toxicology, vol. 38, No. 12, Dec. 2000, Published Online Oct. 9, 2000, 10 pages. cited by applicant
Mosnacek, J. et al., “New combined phenol/hindered amine photo- and thermal-stabilizers based on toluene-2,4-diisocyanate,” Polymer Degradation and Stability, vol. 80, No. 1, Jan. 2003, 14 pages. cited by applicant
Shealy, Y. et al., “Inhibition of Papilloma Formation by Analogues of 7,8-Dihydroretinoic Acid,” Journal of Medical Chemistry, vol. 46, No. 10, May 8, 2003, Published Online Apr. 12, 2003, 9 pages. cited by applicant
Murakami, Y. et al., “An ortho dimer of butylated hydroxyanisole inhibits nuclear factor kappa B activation and gene expression of inflammatory cytokines in macrophages stimulated by Porphyromonas gingivalis fimbriae,” Archives of Biochemistry and Biophysics, vol. 449, No. 1-2, May 15, 2006, Published Online Mar. 3, 2006, 7 pages. cited by applicant
Soubra, L. et al., “Dietary exposure of children and teenagers to benzoates, sulphites, butylhydroxyanisol (BHA) and butylhydroxytoluen (BHT) in Beirut (Lebanon),” Regulatory Toxicology and Pharmacology, vol. 47, No. 1, Feb. 2007, Published Online Sep. 20, 2006, 10 pages. cited by applicant
Iranpoor, N. et al., “Easily Prepared Azopyridines As Potent and Recyclable Reagents for Facile Esterification Reactions. An Efficient Modified Mitsunobu Reaction,” Journal of Organic Chemistry, vol. 73, No. 13, May 31, 2008, 6 pages. cited by applicant
Qian, B. et al., “Macrophage Diversity Enhances Tumor Progression and Metastasis,” Cell, vol. 141, No. 1, Apr. 2, 2010, 13 pages. cited by applicant
Zhang, Y. et al., “ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages,” Cell Research, vol. 23, No. 7, Jul. 2013, Published Online Jun. 11, 2013, 17 pages. cited by applicant
Shindo, R. et al., “Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation,” Biochemical and Biophysical Research Communications, vol. 436, No. 2, Jun. 28, 2013, Available Online May 29, 2013, 5 pages. cited by applicant
Phakodee, W. et al., “Ph3P-I2 mediated aryl esterification with a mechanistic insight,” Tetrahedron Letters, vol. 57, No. 19, May 11, 2016, 3 pages. cited by applicant
ISA State Intellectual Property Office of the People's Republic of China, International Search Report Issued in Application No. PCT/CN2017/074386, dated May 19, 2017, WIPO, 4 pages. cited by applicant
State Intellectual Property Office of the People's Republic of China, Office Action and Search Report Issued in Application No. 201610037849.5, dated Aug. 23, 2018, 19 pages. (Submitted with Partial Translation). cited by applicant
Russian Federal Institute of Industrial Property, Office Action Issued in Application No. 2018111766/04(018284), dated Oct. 24, 2018, Saint Petersburg, Russia, 17 pages. cited by applicant
Russian Federal Institute of Industrial Property, Office Action Issued in Application No. 2018111766/04(018284), dated Apr. 19, 2019, Saint Petersburg, Russia, 14 pages. cited by applicant

edspgr.11738000